Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data

Clin Res Hepatol Gastroenterol. 2023 Aug;47(7):102162. doi: 10.1016/j.clinre.2023.102162. Epub 2023 Jun 10.

Abstract

The fibrolamellar variant of hepatocellular carcinoma makes up a small percentage of liver tumors. Despite being a subset, it has been noted in the literature to have variations in terms of its epidemiology and intervention recommendations. Using the Surveillance, Epidemiology, and End Results database, 339 cases from 1988 to 2016 were studied. Favorable prognostic epidemiological factors included male sex, younger ages, and white race. Those who underwent any lymph node resection (combined with liver resection) did better than those without lymph node resection; chemotherapy proved beneficial for those where surgery was contraindicated. To our knowledge, this report is the largest conglomerate dataset analyzing prognostic profiles and treatment strategies for fibrolamellar hepatocellular carcinoma.

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Hepatectomy
  • Humans
  • Liver Neoplasms* / pathology
  • Male
  • Prognosis

Supplementary concepts

  • Fibrolamellar hepatocellular carcinoma